0
0
12/8/23 at 2:40pm
Organization
Cancertherapyadvisor.com
Author
Bryant Furlow
39 words
0
Comments
T-DM1 is not a viable alternative to standard trastuzumab, pertuzumab, and docetaxel for elderly patients with advanced HER2+ breast cancer, new data suggest.
You are the first to view
https://www.cancertherapyadvisor.com/home/news/conference-coverage/san-antonio-breast-cancer-symposium-sabcs/sabcs-2023/t-dm1-falls-short-in-elderly-patients-with-advanced-her2-breast-cancer/
Create an account
or login to join the discussion